Merck Inks Deal For Generic Fosamax: Report

Law360, New York (January 11, 2008, 12:00 AM EST) -- With its main patent for Fosamax set to expire in February, Merck & Co. has reportedly struck an authorized generic deal with an anonymous company to market a generic copy of its popular osteoporosis drug, which could be on store shelves as early as next month.

Merck, based in Whitehouse Station, N.J., declined on Friday to reveal the name of the generics firm that is a party to the deal, according to a Dow Jones news report.

Merck’s authorized generic deal is a setback for Teva...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.